Increased Cell Membrane Fluidity May Improve Sensitivity to Ovarian Cancer Therapy

Increased Cell Membrane Fluidity May Improve Sensitivity to Ovarian Cancer Therapy
Cell membrane fluidity may determine ovarian cancer response to the anti-rheumatic drug Ridaura (auranofin) currently in trials for epithelial ovarian cancer, researchers found. The study, “Linking genotoxicity and cytotoxicity with membrane fluidity: A comparative study in ovarian cancer cell lines following exposure to auranofin,” published in Mutation Research/Genetic Toxicity and Environmental Mutagenesis, shows that greater

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *